GlaxoSmithKline's decision to shrink its work in the neuroscience field will cost about 50 R&D jobs in the U.S., with about half of those workers being cut from operations in Research Triangle Park. Spokeswoman Kathy Pitman tells MedCityNews that the cuts were made among staffers engaged in late-stage clinical trial work. "We scaled back on early stage research, which means there's not as much coming through that needs later stage clinical trials." GSK earlier announced plans to reduce its investment in neuroscience R&D, where new drugs often fail during clinical studies. Report